Premium
Multi‐Center Comparison of Response to a Single Tablet of Sumatriptan 85 mg and Naproxen 500 mg vs Usual Therapy Treating Multiple Migraine Attacks as Measured by the Completeness of Response Survey
Author(s) -
Cady Roger,
Banks Jim,
Nett Robert B.,
Goldstein Jerome,
Bennett Nathan,
Turner Ira M.,
Ruoff Gary E.,
Landy Stephen H.,
Farmer Kathleen,
Juhász Márta,
Tarrasch Jeanne,
Runken M. Chris
Publication year - 2011
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2011.01912.x
Subject(s) - migraine , medicine , sumatriptan , nap , migraine treatment , physical therapy , acute migraine , anesthesia , alternative medicine , psychology , receptor , pathology , neuroscience , agonist , placebo
( Headache 2011;51:961‐970) Objective.— To investigate a broad definition of migraine resolution that extends beyond specific migraine‐associated diagnostic symptoms as measured by the Completeness of Response Survey. Methods.— Conducted at 8 sites, 135 subjects treated migraines with SumaRT/Nap over 2 months. To measure subjects' experiences with SumaRT/Nap compared to their usual migraine medication, the Headache Impact Test, Revised Patient Perception of Migraine Questionnaire, and Completeness of Response Survey were administered at baseline and at 2 months. Results.— The effects of the study medicine compared to the subjects' usual migraine medicine reached statistical significance in decreasing headache severity, lessening of associated symptoms, and attaining complete relief with a single dose (60.04% of attacks resolved at 2 hours post‐treatment). Conclusion.— Compared to a subject's usual treatment, SumaRT/Nap used early and consistently for treatment of acute migraine offers important clinical improvements, including lessening of associated symptoms beyond International Headache Society criteria.